Key result
ApoE ɛ4 genotype was significantly associated with cognitive impairment (AD/MCI combined) among older adults in Panama (OR 5.14; 95% CI 2.11-12.52).
Population
259 older adults in Panama, including those diagnosed with Alzheimer's disease, mild cognitive impairment…
Design
Case-control
Authors
Loading...
Does not support genetic screening yet; extends ApoE ɛ4 associations to Panama but leaves prospective validation open.
Case-Control (n=259)
Odds Ratio: 5.14 (95% CI 2.11–12.52)
Age and the ApoE ɛ4 allele are significant risk factors for cognitive impairment in older adults in Panama, underscoring the potential utility of genetic screening in this population.
Villarreal et al. (2016) conducted a case-control in Alzheimer's disease and mild cognitive impairment (n=259). ApoE ɛ4 genotype vs. Absence of ApoE ɛ4 genotype / Controls was evaluated on Cognitive impairment (AD/MCI combined) (OR 5.14, 95% CI 2.11-12.52). ApoE ɛ4 genotype was significantly associated with cognitive impairment (AD/MCI combined) among older adults in Panama (OR 5.14; 95% CI 2.11-12.52).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: